Social Responsibility

Sustainable Development

Public welfare activity

Hunan Xianshi Pharmaceutical Receives NMPA Marketing Approval for Two Strengths of Dapoxetine Hydrochloride Tablets

Hunan Xianshi Pharmaceutical Receives NMPA Marketing Approval for Two Strengths of Dapoxetine Hydrochloride Tablets

CHANGSHA, Jan 09, 2026 — Hunan Xianshi Pharmaceutical Co., Ltd. has obtained marketing authorization from the National Medical Products Administration (NMPA) for Dapoxetine Hydrochloride Tablets in two specifications: 30 mg and 60 mg.

→

View Details

01-09

2026

Since November 2025, these new regulations have been in effect! (With the latest updates for 2026 included.)

Since November 2025, these new regulations have been in effect! (With the latest updates for 2026 included.)

Since November 2025, a series of new regulations on pharmaceutical oversight have been progressively implemented. Let’s take a look at which ones directly affect you.

→

View Details

01-03

2026

Hunan Xianshi Pharmaceutical Attracts Wide Attention at PHARMCHINA 91st National Pharmaceutical Fair in Nanjing

Hunan Xianshi Pharmaceutical Attracts Wide Attention at PHARMCHINA 91st National Pharmaceutical Fair in Nanjing

NANJING, Nov 26, 2025 — The 91st National Pharmaceutical Fair (PHARMCHINA) was held at Nanjing International Expo Center from November 19 to 21. The exhibition gathered over 2,000 top pharmaceutical enterprises and more than 100,000 industry practitioners, acting as a key platform for displaying industrial trends, showcasing corporate strengths and developing commercial cooperation.

→

View Details

11-26

2025

Xianshi Pharmaceutical’s Mannitol–Sorbitol Injection has initiated Phase III clinical trials, with intracranial hypertension as the indication.

Xianshi Pharmaceutical’s Mannitol–Sorbitol Injection has initiated Phase III clinical trials, with intracranial hypertension as the indication.

According to data from the Clinical Trial Registration and Information Disclosure Platform, a multi-center, randomized, double-blind, positive-controlled Phase III clinical study evaluating the safety and efficacy of mannitol–sorbitol injection for the treatment of intracranial hypertension has been initiated by Hunan Xianshi Pharmaceutical Co., Ltd. The clinical trial registration number is CTR20254523, and the date of the initial public disclosure was November 13, 2025.

→

View Details

11-21

2025

Hunan Xianshi Pharmaceutical cordially invites you to visit Booth 8E28-2 in Hall 8 at the 91st National Pharmaceutical Fair!

Hunan Xianshi Pharmaceutical cordially invites you to visit Booth 8E28-2 in Hall 8 at the 91st National Pharmaceutical Fair!

CHANGSHA, Nov 7, 2025 — Hunan Xianshi Pharmaceutical Co., Ltd. will participate in the 91st National Pharmaceutical Fair from November 19 to 21. Its exhibition booth is located at Booth 8E28-2, Hall 8, where the company will display a complete lineup of core commercial products and pipeline candidates.

→

View Details

11-07

2025

< 123 >